VIRX (Viracta Therapeutics) FCF Margin %: 0.00% (As of Sep. 2024)


What is Viracta Therapeutics FCF Margin %?

Viracta Therapeutics VIRX FCF Margin % is 0.00% as of Sep. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Viracta Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-7.09 Mil. Viracta Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Viracta Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Viracta Therapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Viracta Therapeutics's FCF Margin % or its related term are showing as below:


VIRX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Viracta Therapeutics FCF Margin % Related Terms

Viracta Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics FCF Margin % Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Margin %
0.00 0.00 0.00 0.00

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VIRX vs TSOI, CYTOF, TRVN: FCF Margin % Comparison

For the Biotechnology subindustry, Viracta Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's FCF Margin % falls into.


Viracta Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Viracta Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-40.03/0
= %

Viracta Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-7.093/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Viracta Therapeutics (VIRX) has a FCF Margin % of 0.00% as of Sep. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' FCF Margin % too high?
Viracta Therapeutics' current FCF Margin % is 0.00%.
How does Viracta Therapeutics' FCF Margin % compare to TSOI and CYTOF?
Viracta Therapeutics' FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current FCF Margin % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.